Overexpression of small ubiquitin-related modifier-1 and sumoylated Mdm2 in oral squamous cell carcinoma: Possible involvement in tumor proliferation and prognosis

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 517-524

  Katayama, Akihiro ^a   Ogino, Takeshi ^a   Bandoh, Nobuyuki ^a   Takahara, Miki ^a   Kishibe, Kan ^a   Nonaka, Satoshi ^a   Harabuchi, Yasuaki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Local control; Mdm2; Prognostic factor; SUMO 1

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2; SUMO PROTEIN; SUMO1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MDM2; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 38449103757     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.517     Document Type: Article

References (30)

1. Hochstrasser M: Evolution and function of ubiquitin-like protein-conjugation systems. Nat Cell Biol 2: 153-157, 2000.
2. Yeh ET, Gong L and Kamitani T: Ubiquitin-like proteins: new wines in new bottles. Gene 248: 1-14, 2000.
3. Melchior F: SUMO - nonclassical ubiquitin. Annu Rev Cell Dev Biol 16: 591-626, 2000.
4. Sternsdorf T, Jensen K and Will H: Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 139: 1621-1634, 1997. (Pubitemid 28079228)
5. Bies J, Markus J and Wolff L: Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem 277: 8999-9009, 2002.
6. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y and Dejean A: c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem 275: 13321-13329, 2000.
7. Alarcon-Vargas D and Ronai Z: SUMO in cancer - wrestlers wanted. Cancer Biol Ther 1: 237-242, 2002.
8. Xirodimas DP, Chisholm J, Desterro JM, Lane DP and Hay RT: P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 528: 207-211, 2002. (Pubitemid 35258025)
9. Chen L and Chen J: MDM2-ARF complex regulates p53 sumoylation. Oncogene 22: 5348-5357, 2003.
10. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
11. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997.
12. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R and Gu W: Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302: 1972-1975, 2003.
13. Lee MH, Lee SW, Lee EJ, Choi SJ, Chung SS, Lee JI, Cho JM, Seol JH, Baek SH, Kim KI, Chiba T, Tanaka K, Bang OS and Chung CH: SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol 8: 1424-1431, 2006.
14. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S and Theillet C: Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60: 1077-1083, 2000.
15. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ and Fontana JA: p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 74: 529-534, 1997.
16. Shimada Y, Imamura M, Shibagaki I, Tanaka H, Miyahara T, Kato M and Ishizaki K: Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 226: 162-168, 1997. (Pubitemid 28047538)
17. Endo K, Ueda T, Ohta T and Terada T: Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 20: 209-215, 2000.
18. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T and Baba S: Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 59: 615-620, 2002.
19. Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S and Harabuchi Y: Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer 94: 1968-1680, 2002.
20. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, De The H, Hay RT and Freemont PS: SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 112: 381-393, 1999.
21. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
22. Momand J and Zambetti GP: Mdm-2: 'big brother' of p53. J Cell Biochem 64: 343-352, 1997.
23. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G and Barbareschi M: mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175: 31-38, 1995.
24. Abdel-Fattah G, Yoffe B, Krishnan B, Khaoustov V and Itani K: MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J Gastrointest Surg 4: 109-114, 2000.
25. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, Meyer F and Fradet Y: Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5: 4079-4084, 1999. (Pubitemid 30013788)
26. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C: Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5: 2082-2088, 1999.
27. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, Cordon-Cardo C and Osman I: HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 94: 1803-1806, 2002.
28. Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S and Zhang R: MDM2 oncogene as a target for cancer therapy: an antisense approach. Int J Oncol 15: 653-660, 1999.
29. Chen L, Agrawal S, Zhou W, Zhang R and Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 95: 195-200, 1998.
30. Chen L, Lu W, Agrawal S, Zhou W, Zhang R and Chen J: Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 5: 21-34, 1999. (Pubitemid 29282094)